A Prospective study assessing the safety and efficacy of apatinib combined with concurrent whole brain radiation therapy in Non-small-cell-lung-cancer patients with brain metastases
Latest Information Update: 23 Nov 2021
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Brain metastases; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 23 Nov 2021 New trial record